New and experimental HIV treatments: latest news

New and experimental HIV treatments resources

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

    Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

    16 September 2014 | NATAP
  • Long acting HIV drugs to be developed

    HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

    15 September 2014 | University of Liverpool press release
  • New medicines in development give hope to patients with HIV/AIDS

    America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

    11 September 2014 | Pharmaceutical Research and Manufacturers of America
  • New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

    BMS-986001, a novel thymidine analog NRTI (nucleoside reverse transcriptase inhibitor) being developed by Oncolys BioPharma, when combined with efavirenz (Sustiva, Stocrin) and lamivudine (3TC, Epivir), was found to have comparable efficacy to tenofovir (Viread) in treatment-naive patients living with HIV, according to phase-2b study results presented by Samir K. Gupta, M.D., M.S., at ICAAC 2014 in Washington, D.C.

    10 September 2014 | The Body
  • Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

    A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

    10 September 2014 | HIVand hepatitis.com
  • New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

    An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

    09 September 2014 | HIVandhepatitis.com
  • EU marketing authorization for ViiV Healthcare HIV drug Triumeq

    The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

    04 September 2014 | Pharma Letter
  • The Role of Triumeq in HIV Treatment

    The approval of Triumeq, the single-tablet coformulation of abacavir, lamivudine and the integrase inhibitor dolutegravir, is an important step forward for antiretroviral therapy. Whereas all of the previously approved single-tablet regimens (STRs) contain tenofovir (Viread), which some people can't take, usually because of kidney disease, Triumeq does not contain tenofovir.

    04 September 2014 | The Body
  • Aiming For HIV's Weak Spot - The new generation of gp120 entry inhibitors

    A small molecule (green) binds within a cavity on the HIV protein gp120. Amino acid residues that contribute only to binding affinity are colored blue, and those that contribute strongly to binding as well as the protein's conformational change are ...

    02 September 2014 | C&EN - Chemical and Engineering News
  • FDA Approves New Single-Tablet HIV Regimen, Triumeq

    The U.S. Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare's single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (Kivexa/Epzicom) and is the first single-tablet regimen to receive approval that does not contain tenofovir.

    26 August 2014 | Aidsmeds.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.